GC
PDLI

Guggenheim Capital’s PDL BioPharma, Inc. PDLI Stock Holding History

Guggenheim Capital’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-69,050
Closed -$234K – 2928
2017
Q3 		$234K Sell
69,050
-11,043
-14% -$30.7K ﹤0.01% 2588
2017
Q2 		$198K Sell
80,093
-4,877
-6% -$11.2K ﹤0.01% 2643
2017
Q1 		$192K Sell
84,970
-4,319
-5% -$9.55K ﹤0.01% 2632
2016
Q4 		$189K Sell
89,289
-46,253
-34% -$129K ﹤0.01% 2699
2016
Q3 		$454K Sell
135,542
-466,755
-77% -$1.48M ﹤0.01% 2419
2016
Q2 		$1.89M Sell
602,297
-159,775
-21% -$533K 0.01% 1599
2016
Q1 		$2.54M Sell
762,072
-1,134,149
-60% -$3.54M 0.01% 1417
2015
Q4 		$6.71M Sell
1,896,221
-218,049
-10% -$913K 0.02% 898
2015
Q3 		$10.6M Sell
2,114,270
-390,774
-16% -$2.24M 0.03% 724
2015
Q2 		$16.1M Buy
2,505,044
+1,067,397
+74% +$7.15M 0.04% 667
2015
Q1 		$10.1M Buy
1,437,647
+316,032
+28% +$2.29M 0.02% 846
2014
Q4 		$8.65M Buy
1,121,615
+202,755
+22% +$1.6M 0.02% 894
2014
Q3 		$6.86M Sell
918,860
-475,485
-34% -$4.41M 0.02% 1054
2014
Q2 		$13.5M Buy
1,394,345
+856,670
+159% +$7.64M 0.03% 771
2014
Q1 		$4.47M Sell
537,675
-328,750
-38% -$2.82M 0.01% 1184
2013
Q4 		$7.31M Sell
866,425
-977,335
-53% -$8.24M 0.02% 929
2013
Q3 		$14.7M Buy
1,843,760
+1,066,634
+137% +$8.57M 0.05% 654
2013
Q2 		$6M Buy
+777,126
New +$6.06M 0.03% 976

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Guggenheim Capital's PDLI Position: Q4 2017 in Review

Guggenheim Capital sold out of PDL BioPharma, Inc. (PDLI) in Q4 2017, closing a stake of 69,050 shares — an estimated $234K sold.

Guggenheim Capital first reported a position in PDLI in Q2 2013 and held it in 18 quarters. The position peaked at $16.1M in Q2 2015. 187 funds tracked by Wall St. Rank hold PDLI as of Q4 2017.

  • Guggenheim Capital reported no remaining PDL BioPharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Guggenheim Capital sold 69,050 PDL BioPharma, Inc. shares in Q4 2017, an estimated $234K.
  • Guggenheim Capital first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 18 quarters.
  • Guggenheim Capital's PDL BioPharma, Inc. position peaked at $16.1M in Q2 2015.
  • 187 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2017.

Based on Guggenheim Capital's 13F filing for Q4 2017, filed 14 Feb 2018.